Compare STRA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | NVCR |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1996 | 2015 |
| Metric | STRA | NVCR |
|---|---|---|
| Price | $81.59 | $17.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $87.00 | $28.08 |
| AVG Volume (30 Days) | 218.1K | ★ 1.1M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | 15.85 | ★ 21.79 |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $997,137,000.00 | $655,353,000.00 |
| Revenue This Year | $4.71 | $7.72 |
| Revenue Next Year | $4.67 | $6.74 |
| P/E Ratio | $25.95 | ★ N/A |
| Revenue Growth | ★ 57.23 | 8.28 |
| 52 Week Low | $69.70 | $9.82 |
| 52 Week High | $89.73 | $21.45 |
| Indicator | STRA | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 53.88 |
| Support Level | $77.33 | $16.33 |
| Resistance Level | $84.83 | $18.41 |
| Average True Range (ATR) | 2.25 | 0.80 |
| MACD | -0.23 | -0.01 |
| Stochastic Oscillator | 36.16 | 59.21 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.